Pulmonary Vascular Changes in Asthma and COPD|
The involvement of residential cells such as endothelial cells, smooth muscle cells and pulmonary fibroblasts, all appear to have a crucial role in the progression of vascular inflammation and remodelling. The regulatory abnormalities, growth factors and mediators implicated in the pulmonary vascular changes of asthma and chronic obstructive pulmonary disease (COPD) subjects and potential therapeutic targets are reviewed by the authors. [Pulm Pharmacol Ther] Abstract
Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Aduro Expands Collaboration with Johnson & Johnson Innovation and Janssen for Lung Cancer Immunotherapies|
Aduro BioTech, Inc., announced that it has entered into its second agreement with Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform. [Aduro BioTech, Inc. (Business Wire)] Press Release
Catalent Applied Drug Delivery Institute to Collaborate with Lung Cancer Alliance to Conduct Patient Research
The Catalent Applied Drug Delivery Institute announced that it is to collaborate with the Lung Cancer Alliance on patient research in early October. The collaboration will focus on patient and caregiver insights, in order to better understand the unmet needs of patients when managing lung cancer, also the impact that treatment has on the patient overall, managing other disease states, and daily living. [Catalent, Inc] Press Release
ASCO Endorses CAP/IASLC/AMP Guideline on EGFR and ALK Molecular Testing for Patients with Lung Cancer
The American Society of Clinical Oncology (ASCO) issued an endorsement of the joint College of American Pathologists (CAP)/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline on molecular testing for selection of patients with lung cancer for therapies targeting epidermal growth factor receptor and anaplastic lymphoma kinase.
[American Society of Clinical Oncology]
FDA Approves Esbriet (Pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States
Roche announced that the U.S. Food and Drug Administration (FDA) has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis in the United States. [Hoffmann-La Roche Ltd.] Press Release
From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.